Recent Updates
Recently added Catalysts

Leukemia: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$176Muniverse median $1.20B
Allocated capital$176M$176M competing
Phase 3 or filed00 mid, 1 early
Pure plays1this indication only
Capital rank261/299crowding rank 263

Leukemia is uncontested. Molecular Partners (MOLN) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with MP0533 monotherapy in phase 1.

There is no public comparable to price it against, and MOLN runs clinical programmes in this indication and nothing else, so its $176M market cap is a direct read on what the market thinks this programme is worth.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$176M of allocated capital sits in Leukemia, ranking it 261st of 299 indications by the money committed to it.

Companies developing drugs for Leukemia 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
MOLNMolecular PartnersMP0533 monotherapyPhase 11$176MYes1 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Leukemia counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Leukemia has one competitor and a median of $176M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Advanced Hepatocellular Carcinoma1 company · $175M · median $175MUncontestedChronic Myeloid Leukemia1 company · $180M · median $1.6BUncontestedPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia1 company · $180M · median $1.6BUncontestedLiposarcoma1 company · $180M · median $1.6BUncontestedMetastatic Lung Cancer1 company · $162M · median $486MUncontestedRelapsed and Refractory Multiple Myeloma1 company · $156M · median $156MUncontestedT-Cell Lymphoblastic Leukemia/Lymphoma2 companies · $149M · median $374MOrphan cornerRefractory/ Relapsed Non-Hodgkin Lymphoma1 company · $203M · median $610MUncontested

Leukemia pipeline questions

Which biotech companies are developing drugs for Leukemia?

Molecular Partners (MOLN, MP0533 monotherapy, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Leukemia.

How advanced is the Leukemia pipeline?

Of the 1 clinical-stage programme in Leukemia, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Leukemia?

No. MOLN is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Leukemia, which is why the indication is classified as uncontested.

When is the next Leukemia catalyst?

The next dated catalyst in Leukemia is MOLN on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map